<DOC>
	<DOC>NCT02009137</DOC>
	<brief_summary>Expected Total Number of Subjects - Level of significance, alfa 0.05 - Power 0.80 - Mean difference between two treatments is assumed 35 - Standard Deviation is assumed 35. - Follow-up loss is assumed 20% - N=34(each group:17)</brief_summary>
	<brief_title>Efficacy and Safety Study of EVERA to Augment Small Breast</brief_title>
	<detailed_description>Study design - single center, randomized, unblind clinical study Medical device - Investigational Medical Device: EVERA - Comparator: ESTES Process - For eligible subjects, investigator apply Standard Deviation or Comparator on the breast - The Investigational Medical Device is determined by randomization. - Subjects will be applied for 12 weeks. - Subjects will receive Patient Compliance Diary - Subjects will visit the hospital to measure breast volume with VIVID 9i every 2 weeks for 16weeks</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<criteria>Female aged between 24 and 40 BMI of over 20 Subjects who want to augment breasts Subjects who understand the study contents and signed the informed consent Subjects who can follow study procedure Pregnant or Lactating subjects</criteria>
	<gender>Female</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>small breast</keyword>
	<keyword>augmentation</keyword>
	<keyword>breast volume</keyword>
	<keyword>External Soft Tissue Expansion System(ESTES)</keyword>
</DOC>